SCHEMBL13368151

SCHEMBL13368151

COc1ccc(Cc2nc3cc(C)ccc3c(=O)[nH]2)cc1OC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.57
KDM4E B2RXH2 7/20 0.52
ALDH1A1 P00352 4/20 0.52
HPGD P15428 2/20 0.52
ATM Q13315 1/20 0.48
LMNA P02545 3/20 0.48
TDP1 Q9NUW8 1/20 0.48
GAA P10253 1/20 0.47
MAPK1 P28482 3/20 0.47
USP2 O75604 1/20 0.47
ALOX15 P16050 1/20 0.47
CYP3A4 P08684 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
TSHR P16473 1/20 0.46
CCNE2 O96020 1/20 0.46
CDK4 P11802 1/20 0.46
CCND1 P24385 1/20 0.46
CCNE1 P24864 1/20 0.46
CDK2 P24941 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10054202 0.86 POLB (0.53) POLBKDM4EALDH1A1HPGDATM
SCHEMBL403796 0.85 PDE5A (0.64) POLBKDM4EALDH1A1HPGDATM
SCHEMBL404601 0.84 KDM4E (0.56) POLBKDM4EALDH1A1HPGDATM
SCHEMBL17888980 0.83 POLB (0.50) POLBKDM4EALDH1A1HPGDATM
SCHEMBL13367923 0.82 MMP13 (0.53) CCNE2CDK4CCND1CCNE1CDK2
SCHEMBL403588 0.79 PDE5A (0.53) POLBKDM4EALDH1A1HPGDLMNA
SCHEMBL401317 0.78 PDE5A (0.62) POLBKDM4EALDH1A1HPGDLMNA
SCHEMBL405344 0.76 PDE5A (0.63) POLBKDM4EALDH1A1ATMLMNA
SCHEMBL17298075 0.76 TNKS2 (0.64) POLBKDM4EALDH1A1LMNATDP1
SCHEMBL405463 0.75 KDM4E (0.58) KDM4EALDH1A1HPGDATMLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100113484-A1 TREATING AGENT OF UROPATHY ASKA PHARMACEUTICAL CO., LTD. (JP) 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113484-A1 TREATING AGENT OF UROPATHY BPHL, PDE12, UROD POLB 555/4885KDM4E 4291/4885ALDH1A1 762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.